Evidence map›Paper›PMID 24383813›Full record

ArticleOrganic letters2014

Lomaiviticin biosynthesis employs a new strategy for starter unit generation.

Abraham J Waldman, Emily P Balskus

Abstract read
In one paragraph

Article in Organic letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Abraham J WaldmanDepartment of Chemistry and Chemical Biology, Harvard University , Cambridge, Massachusetts 02138, United States.
Emily P Balskus

Funding

Principles of Scientific Citizenship: Ethics, Communication, and Leadership for ScientistsT32GM095450 · NIGMS · HARVARD UNIVERSITY · PI WALKER, SUZANNE · 2011 to 2020
$3.5M
Biocompatible Chemistry for In Vivo Metabolite ModificationDP2GM105434 · NIGMS · HARVARD UNIVERSITY · PI BALSKUS, EMILY PATRICIA · 2012 to 2012
$2.5M
NCCDPHP CDC HHS DP2 GM105434NIGMS NIH HHS DP2 GM105434NIGMS NIH HHS GM095450NIGMS NIH HHS T32 GM095450
6 · The paper itself

Abstract

Lomaiviticin biosynthesis is thought to utilize a propionyl starter unit for a type II polyketide synthase (PKS). Discovery of the lomaiviticin (lom) biosynthetic gene cluster suggested an unusual method for starter unit generation involving a bifunctional acyltransferase/decarboxylase (AT/DC) thus far observed only in type I PKS pathways. In vitro biochemical characterization of AT/DC Lom62 confirmed its ability to generate a propionyl-acyl carrier protein (ACP), revealing a new role for this enzymatic activity within natural product biosynthesis.

Indexed as

Acyl Carrier ProteinAcyltransferasesAmino Acid SequenceAngucyclines and AngucyclinonesFluorenesMolecular StructureMultigene FamilyPolyketide SynthasesStreptomycesAcyl Carrier ProteinAcyltransferasesAngucyclines and AngucyclinonesFluoreneslomaiviticin APolyketide Synthases

Identifiers

PMID24383813
PMCPMC3965344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.